03 June 2015
Privately-held Switzerland-headquartered Ferring Pharmaceuticals has signed an agreement, that gives NovaMedica the rights for commercialization of a range of Ferring’s line of innovative gastroenterological prescription drug products for the treatment of inflammatory bowel disease (IBD) in the Russian market.
“We are glad to collaborate with NovaMedica and believe that this company is the right choice because of its long-term strategy targeted at bringing innovative gastroenterological products to Russian patients”
The product line includes established and soon-to-launch treatments for inflammatory bowel diseases: ulcerative colitis, Crohn's disease and bleeding from esophageal varices.
Employees of marketing and sales departments, medical advisors and representatives of NovaMedica will market and support the products in the Russian market.
PrintOctober 10 – World Mental Health Day
10 October 2024
Long-Term Game: NovaMedica Experts at the Pharma Marketing Conference
10 October 2024
NovaMedica in the TOP-1000 Russian Managers Rating
28 September 2024
Novel nanoemulsion-based delivery of antimycobacterial drug
31 October 2024
Russia will create a National Center for Genetic Resources of Microorganisms
31 October 2024
Optimising drug release of personalised 3D printed tablets
30 October 2024
Immunotherapy treatment enhances lymphoma survival, landmark study shows
30 October 2024